Rachel Bryan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rachel Bryan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alison Williams
Swansea University, UK
2 shared publications- Jeffrey K. Aronson
Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
2 shared publications - Sue Jordan
Swansea University
2 shared publications Alison J. Williams
College of Arts and Humanities Swansea University Swansea UK
1 shared publicationElizabeth Gagen
Aberystwyth University, Aberystwyth, UK
1 shared publicationGwendoline I Wilson
Swansea University, Swansea, UK
1 shared publication
Latest Publications
- 14 May 2025
- Published by Swansea University
Linguistic Latent Conditions in International Nonproprietary Names of Medicines: Linguistic Drivers of Look-Alike Sound-Alike Errors and Implications in Russian and Italian Drug Nomenclatures
This thesis has set out to identify linguistic latent conditions in international drug names. To achieve this aim, three research questions (RQ) are asked: RQ1, How can the International Nonproprietary Name (INN) nomenclature be characterised in linguistic terms?; RQ2, To what extent are any of the linguistic features described in answer to RQ1 associated with the occurrence of Look-Alike Sound-Alike (LASA) error?; and RQ3, How can Russian-language and Italian-language pharmaceutical nomenclature be characterised in linguistic terms, and what are the implications of findings from RQ2 for these languages? LASA errors are a type of medication error between similar drug names and constitute a significant threat to patient safety, e.g. hydralazine and hydroxyzine. They are highlighted in the World Health Organization’s 2017 global patient safety challenge Medication without harm. The thesis frames linguistic features that increase the risk of LASA errors as a type of latent condition in the healthcare system that creates ‘accident opportunities’, under Reason’s human error theory. Three shortcomings in the literature are addressed: morphosemantic features of drug nomenclature (most studies look at formal features such as name length), linguistic properties of generic names (most look at brand names), and drug nomenclature in languages other than English. One linguistic latent condition is identified - initial trigram frequency – which leads to a suggestion for manufacturers and regulators to consider encouraging diversity in the beginning strings of names. Several other linguistic variables show potential associations with LASA error that merit further research but fall short of sufficient empirical evidence to make a policy recommendation. Two non-linguistic confounders are identified that significantly drive risk: prescribing frequency and year of approval. Analyses are complemented by two case studies of Russian-language INNs and Italian Common Names.
- 14 May 2025
- Published by Swansea University
Linguistic Latent Conditions in International Nonproprietary Names of Medicines: Linguistic Drivers of Look-Alike Sound-Alike Errors and Implications in Russian and Italian Drug Nomenclatures
This thesis has set out to identify linguistic latent conditions in international drug names. To achieve this aim, three research questions (RQ) are asked: RQ1, How can the International Nonproprietary Name (INN) nomenclature be characterised in linguistic terms?; RQ2, To what extent are any of the linguistic features described in answer to RQ1 associated with the occurrence of Look-Alike Sound-Alike (LASA) error?; and RQ3, How can Russian-language and Italian-language pharmaceutical nomenclature be characterised in linguistic terms, and what are the implications of findings from RQ2 for these languages? LASA errors are a type of medication error between similar drug names and constitute a significant threat to patient safety, e.g. hydralazine and hydroxyzine. They are highlighted in the World Health Organization’s 2017 global patient safety challenge Medication without harm. The thesis frames linguistic features that increase the risk of LASA errors as a type of latent condition in the healthcare system that creates ‘accident opportunities’, under Reason’s human error theory. Three shortcomings in the literature are addressed: morphosemantic features of drug nomenclature (most studies look at formal features such as name length), linguistic properties of generic names (most look at brand names), and drug nomenclature in languages other than English. One linguistic latent condition is identified - initial trigram frequency – which leads to a suggestion for manufacturers and regulators to consider encouraging diversity in the beginning strings of names. Several other linguistic variables show potential associations with LASA error that merit further research but fall short of sufficient empirical evidence to make a policy recommendation. Two non-linguistic confounders are identified that significantly drive risk: prescribing frequency and year of approval. Analyses are complemented by two case studies of Russian-language INNs and Italian Common Names.
- Open Access
- 21 January 2022
- Published by Springer Nature in SN Social Sciences
- Vol. 2 (2) , 1-27
Reaching out to the hard-to-reach: mixed methods reflections of a pilot Welsh STEM engagement project
Despite years of targeted interventions, young people experiencing socio-economic deprivation are still under-represented in those studying STEM (science, technology, engineering, and mathematics) subjects post-16 and in higher education STEM pathways. We surveyed 61 young people who had participated in the S4 programme in South Wales, UK, and interviewed three of their teachers. Using the theoretical lens of science capital, we asked them about the S4 programme, and their views of science and education in terms of aspirations, attainment, and social obstacles. Whilst widely outdated, a ‘deficit model’ of aspiration raising still guides STEM outreach policy in Wales and we consider the answers to our survey in light of this. Broadly, our participants are enthusiastic and ambitious, and confident in their abilities in both science and wider skill areas. However, we found certain aspects of ambition were linked to socio-economic status. For example, whilst most young people we surveyed aspire to go university, those who do not cite different reasons depending on their socio-economic status. Despite high aspirations around science and education, teachers cited low literacy and numeracy, household poverty, entrenched generational unemployment, rural isolation, disabilities, caring responsibilities, and teenage pregnancy as barriers to higher education for their pupils. Importantly, S4's intervention had the greatest impact with those in the extremes of socio-economic deprivation, particularly in terms of bolstering existing science and education aspirations and increasing the ‘thinkability’ of attending university. Our findings contradict accepted thinking on science and education aspirations in that rather than participation in higher education being motivated by a lack of science and education aspiration or the discourse of family habitus ("people like us"), young people seem to be starkly aware of the very real socio-economic obstacles. We found no poverty of science and education aspiration in the participants we surveyed, and encourage a policy move away from the deficit model of raising science and education aspirations that will take a more nuanced view of widening access to STEM education and higher education in general in Wales.
- 21 January 2022
- Published by Springer Nature in SN Social Sciences
- Vol. 2 (2) , 1-27
Open AccessReaching out to the hard-to-reach: mixed methods reflections of a pilot Welsh STEM engagement project
Despite years of targeted interventions, young people experiencing socio-economic deprivation are still under-represented in those studying STEM (science, technology, engineering, and mathematics) subjects post-16 and in higher education STEM pathways. We surveyed 61 young people who had participated in the S4 programme in South Wales, UK, and interviewed three of their teachers. Using the theoretical lens of science capital, we asked them about the S4 programme, and their views of science and education in terms of aspirations, attainment, and social obstacles. Whilst widely outdated, a ‘deficit model’ of aspiration raising still guides STEM outreach policy in Wales and we consider the answers to our survey in light of this. Broadly, our participants are enthusiastic and ambitious, and confident in their abilities in both science and wider skill areas. However, we found certain aspects of ambition were linked to socio-economic status. For example, whilst most young people we surveyed aspire to go university, those who do not cite different reasons depending on their socio-economic status. Despite high aspirations around science and education, teachers cited low literacy and numeracy, household poverty, entrenched generational unemployment, rural isolation, disabilities, caring responsibilities, and teenage pregnancy as barriers to higher education for their pupils. Importantly, S4's intervention had the greatest impact with those in the extremes of socio-economic deprivation, particularly in terms of bolstering existing science and education aspirations and increasing the ‘thinkability’ of attending university. Our findings contradict accepted thinking on science and education aspirations in that rather than participation in higher education being motivated by a lack of science and education aspiration or the discourse of family habitus ("people like us"), young people seem to be starkly aware of the very real socio-economic obstacles. We found no poverty of science and education aspiration in the participants we surveyed, and encourage a policy move away from the deficit model of raising science and education aspirations that will take a more nuanced view of widening access to STEM education and higher education in general in Wales.
- Open Access
- 15 December 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (2) , 336-351
A systematic literature review of LASA error interventions
Aims: The aim of this systematic review was to explore and evaluate the efficacy of interventions to reduce the prevalence of look‐alike, sound‐alike (LASA) medication name errors.Methods: We conducted a systematic review of the literature, searching PubMed, EMBASE, Scopus and Web of Science up to December 2016, and re‐ran the search in February 2020 for later results. We included studies of interventions to reduce LASA errors and included randomized controlled trials, controlled before‐and‐after studies, and interrupted time series. Details were registered in Prospero (ID: CRD42016048198).Results: We identified six studies that fulfilled our inclusion criteria. All were conducted in laboratories. Given the diversity in the included studies, we did not conduct a meta‐analysis and instead report the findings narratively. The only intervention explored in RCTs was capitalization of selected letters (“Tall Man”), for which we found limited efficacy and no consensus.Conclusions: Tall Man lettering is a marginally effective intervention to reduce LASA errors, with a number of caveats. We suggest that Tall Man gives rise to a “quasi‐placebo effect”, whereby a user derives more benefit from Tall Man lettering if they are aware of its purpose. Keywords: (on scholar one).
- 15 December 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (2) , 336-351
Open AccessA systematic literature review of LASA error interventions
Aims: The aim of this systematic review was to explore and evaluate the efficacy of interventions to reduce the prevalence of look‐alike, sound‐alike (LASA) medication name errors.Methods: We conducted a systematic review of the literature, searching PubMed, EMBASE, Scopus and Web of Science up to December 2016, and re‐ran the search in February 2020 for later results. We included studies of interventions to reduce LASA errors and included randomized controlled trials, controlled before‐and‐after studies, and interrupted time series. Details were registered in Prospero (ID: CRD42016048198).Results: We identified six studies that fulfilled our inclusion criteria. All were conducted in laboratories. Given the diversity in the included studies, we did not conduct a meta‐analysis and instead report the findings narratively. The only intervention explored in RCTs was capitalization of selected letters (“Tall Man”), for which we found limited efficacy and no consensus.Conclusions: Tall Man lettering is a marginally effective intervention to reduce LASA errors, with a number of caveats. We suggest that Tall Man gives rise to a “quasi‐placebo effect”, whereby a user derives more benefit from Tall Man lettering if they are aware of its purpose. Keywords: (on scholar one).
- Open Access
- 21 March 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (2) , 386-394
The problem of look‐alike, sound‐alike name errors: Drivers and solutions
Look‐alike or sound‐alike (LASA) medication names may be mistaken for each other, e.g. mercaptamine and mercaptopurine. If an error of this sort is not intercepted, it can reach the patient and may result in harm. LASA errors occur because of shared linguistic properties between names (phonetic or orthographic), and potential for error is compounded by similar packaging, tablet appearance, tablet strength, route of administration or therapeutic indication. Estimates of prevalence range from 0.00003 to 0.0022% of all prescriptions, 7% of near misses, and between 6.2 and 14.7% of all medication error events. Solutions to LASA errors can target people or systems, and include reducing interruptions or distractions during medication administration, typographic tweaks, such as selective capitalization (Tall Man letters) or boldface, barcoding, and computerized physician order entry.
- 21 March 2020
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 87 (2) , 386-394
Open AccessThe problem of look‐alike, sound‐alike name errors: Drivers and solutions
Look‐alike or sound‐alike (LASA) medication names may be mistaken for each other, e.g. mercaptamine and mercaptopurine. If an error of this sort is not intercepted, it can reach the patient and may result in harm. LASA errors occur because of shared linguistic properties between names (phonetic or orthographic), and potential for error is compounded by similar packaging, tablet appearance, tablet strength, route of administration or therapeutic indication. Estimates of prevalence range from 0.00003 to 0.0022% of all prescriptions, 7% of near misses, and between 6.2 and 14.7% of all medication error events. Solutions to LASA errors can target people or systems, and include reducing interruptions or distractions during medication administration, typographic tweaks, such as selective capitalization (Tall Man letters) or boldface, barcoding, and computerized physician order entry.
- Open Access
- 23 December 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0145431
Patient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names
Confusion between look-alike and sound-alike (LASA) medication names (such as mercaptamine and mercaptopurine) accounts for up to one in four medication errors, threatening patient safety. Error reduction strategies include computerized physician order entry interventions, and ‘Tall Man’ lettering. The purpose of this study is to explore the medication name designation process, to elucidate properties that may prime the risk of confusion. We analysed the formal and semantic properties of 7,987 International Non-proprietary Names (INNs), in relation to naming guidelines of the World Health Organization (WHO) INN programme, and have identified potential for errors. We explored: their linguistic properties, the underlying taxonomy of stems to indicate pharmacological interrelationships, and similarities between INNs. We used Microsoft Excel for analysis, including calculation of Levenshtein edit distance (LED). Compliance with WHO naming guidelines was inconsistent. Since the 1970s there has been a trend towards compliance in formal properties, such as word length, but longer names published in the 1950s and 1960s are still in use. The stems used to show pharmacological interrelationships are not spelled consistently and the guidelines do not impose an unequivocal order on them, making the meanings of INNs difficult to understand. Pairs of INNs sharing a stem (appropriately or not) often have high levels of similarity (<5 LED), and thus have greater potential for confusion. We have revealed a tension between WHO guidelines stipulating use of stems to denote meaning, and the aim of reducing similarities in nomenclature. To mitigate this tension and reduce the risk of confusion, the stem system should be made clear and well ordered, so as to avoid compounding the risk of confusion at the clinical level. The interplay between the different WHO INN naming principles should be further examined, to better understand their implications for the problem of LASA errors.
- 23 December 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (12) , e0145431
Open AccessPatient Safety in Medication Nomenclature: Orthographic and Semantic Properties of International Nonproprietary Names
Confusion between look-alike and sound-alike (LASA) medication names (such as mercaptamine and mercaptopurine) accounts for up to one in four medication errors, threatening patient safety. Error reduction strategies include computerized physician order entry interventions, and ‘Tall Man’ lettering. The purpose of this study is to explore the medication name designation process, to elucidate properties that may prime the risk of confusion. We analysed the formal and semantic properties of 7,987 International Non-proprietary Names (INNs), in relation to naming guidelines of the World Health Organization (WHO) INN programme, and have identified potential for errors. We explored: their linguistic properties, the underlying taxonomy of stems to indicate pharmacological interrelationships, and similarities between INNs. We used Microsoft Excel for analysis, including calculation of Levenshtein edit distance (LED). Compliance with WHO naming guidelines was inconsistent. Since the 1970s there has been a trend towards compliance in formal properties, such as word length, but longer names published in the 1950s and 1960s are still in use. The stems used to show pharmacological interrelationships are not spelled consistently and the guidelines do not impose an unequivocal order on them, making the meanings of INNs difficult to understand. Pairs of INNs sharing a stem (appropriately or not) often have high levels of similarity (<5 LED), and thus have greater potential for confusion. We have revealed a tension between WHO guidelines stipulating use of stems to denote meaning, and the aim of reducing similarities in nomenclature. To mitigate this tension and reduce the risk of confusion, the stem system should be made clear and well ordered, so as to avoid compounding the risk of confusion at the clinical level. The interplay between the different WHO INN naming principles should be further examined, to better understand their implications for the problem of LASA errors.